Some researchers believe that flaws in processes governing production, accumulation or disposal of amyloid protein in the brain are the primary cause of Alzheimer's. AB42 is a particularly sticky variety of amyloid protein fragment that is more likely to aggregate into small clusters and eventually into the plaques that are considered one hallmark of the Alzheimer's brain.
In a new study presented at the 2008 International Conference on Alzheimer's Disease, in Chicago, USA, a team of US researchers reported on a much larger cohort (n=132; aged 45-88 years, mean 65.7). This group included individuals who were non-demented plus those with very mild or mild dementia. Consistent with the prior study, the researchers found a striking inverse relation between brain amyloid and levels of AB42 in CSF.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze